Bortezomib elevated liver transaminases agonist/antagonist monotherapy CY 7 inhibitors Ketoconazole Aminogluthetimide Abiraterone CY 7 inhibition in the adrenal gland results in reduced production of androgens from steroid precursors Second-line therapy in advanced prostate cancer; abiraterone is specifically indicated in men who have progressed after prior docetaxel chemotherapy Nausea and vomiti adrenal insufficiency requiring co-administration of hydrocortiso dermatologic effec elevated liver transaminas neuromuscular effects Abbreviations: D dihydrotestosterone; Gn gonadotropin-releasing hormone; luteinizing hormone.

Asian Journal of Andrology ADT in prostate cancer RM Connolly deemed to have a high  Triciribine risk of disease recurrence. Locally advanced prostate cancer is usually considered very high risk. 4 The various indications for the use of ADT in these settings and the data supporting these indications have been reviewed previously 5 and prostatectomy is adjuvant radiati which has been asso-ciated with improvements in biochemical relapse-free surviv meta-stasis-free survival and OS. are described below . ADT with RT ADT with surgery Neoadjuvant. In an effort to improve prostate cancer ou a number of studies have examined the administration of neoadjuvant ADT prior to radical prostatectomy in men with early-stage prostate cancer. Many of these have randomized men to short-term ADT vs. placebo with some demonstration of a decrease in tumor stage and grade.

Unfortunate these studies did not reveal an improve-ment in long-term oues such as a  Docetaxel 114977-28-5 survival benefit. Other studies have evaluated longer duration of ADT. In a lar prospective phase III tri the ability of months vs. months of neoadjuvant ADT to reduce PSA recurrence rates after radical prostatectomy was exam-ined. Ongoing biochemical and pathological regression of prostate tumors occurred between and months of neoadjuvant A sug-gesting that the optimal duration of neoadjuvant hormonal therapy is longer than months. 9 Despite demonstration of increased patho-logicalplete remissions and clear surgical margins with longer duration of neoadjuvant A studies have failed to detect significant improvements in survival. 0 A recent phase II trial evaluated the benefit of neoadjuvant docetaxel for cycles as well as year of neoadjvuant ADT in patients  buy sodium butyrate with lymph node metastases scheduled to undergo radical prostatectomy. Eleven percent of evaluable patients progressed during therapy and 1 did not achieve a PSA level o ng ml and were not offered primary surgical therapy. Surgery waspleted in the remaind and of tho 0 had no progression year postoperatively .

Eight percent of patients had a pathologicalplete response.  This neoadjuvant approach appeared feasib but longer-term data are necessary to assess survival oues. Adjuvant. The data supporting the use of adjuvant ADT after definitive surgical therapy for early-stage prostate cancer is limited. Ninety-eight men who were found to have pelvic lymph node involvement during radical prostatectomy were randomized to immediate ADT or observation until disease progres-sion. With a median follow-up of yea those assigned   nucleoid immediate ADT had a significant improvement in overall survival 4, P 4), prostate cancer-specific survival and progression-free survival .